MARKET

REVB

REVB

Revelation Biosciences
NASDAQ
1.650
+0.180
+12.24%
After Hours: 1.620 -0.03 -1.82% 19:59 02/06 EST
OPEN
1.490
PREV CLOSE
1.470
HIGH
1.669
LOW
1.410
VOLUME
720.89K
TURNOVER
--
52 WEEK HIGH
55.20
52 WEEK LOW
1.410
MARKET CAP
2.44M
P/E (TTM)
-0.0137
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at REVB last week (0126-0130)?
Weekly Report · 6d ago
Revelation Biosciences Files Prospectus For The Resale Of 4,272,500 Shares Via Warrants For Potential Proceeds Up To ~$14.7M
Benzinga · 01/30 21:20
REVELATION BIOSCIENCES - FILES PROSPECTUS TO RESALE 4.72 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 01/30 21:18
Revelation Biosciences files to sell 4.27M shares of common stock for holders
TipRanks · 01/30 21:10
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
Benzinga · 01/29 15:14
Revelation Biosciences Raises Capital via Warrant Inducement
TipRanks · 01/29 11:36
Revelation Biosciences Raises $7.3 Million Through Unregistered Warrant Exercise
Reuters · 01/29 11:02
Revelation Biosciences Inc trading halted, news pending
TipRanks · 01/28 00:50
More
About REVB
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.

Webull offers Revelation Biosciences Inc stock information, including NASDAQ: REVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REVB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REVB stock methods without spending real money on the virtual paper trading platform.